Neuberger Berman Group LLC Denali Therapeutics Inc. Transaction History

Neuberger Berman Group LLC

  • $123 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Nov 14, 2024
BUY
$16.2 - $23.18 $2.34 Million - $3.35 Million
144,461 New
144,461 $3.1 Million
Q4 2023

Feb 09, 2024
BUY
$16.2 - $23.18 $2.34 Million - $3.35 Million
144,461 New
144,461 $3.1 Million
Q3 2019

Nov 13, 2019
SELL
$15.32 - $21.92 $153,200 - $219,200
-10,000 Closed
0 $0
Q2 2019

Aug 13, 2019
SELL
$18.5 - $28.14 $370,000 - $562,800
-20,000 Reduced 66.67%
10,000 $208,000
Q1 2019

May 13, 2019
BUY
$17.99 - $24.65 $539,700 - $739,500
30,000 New
30,000 $696,000

Others Institutions Holding DNLI

# of Institutions
227
Shares Held
119M
Call Options Held
60.6K
Put Options Held
48.4K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email